Participants completed a battery of 9 neuropsychological measures at baseline and then every 1 to 3 years.
Participants were tested on cognitive and mood measures at baseline, 4 and 24 h post-administration of medication.
Participants completed the EDE interview and self-report measures at baseline, 6 weeks, and posttreatment.Treatment attrition was low, and DBT-AF was rated highly acceptable.
Measures at baseline, post-treatment and 9-month follow-up included BMI, motor development, perceived competence, objectively measured physical activity and performance of an activity of daily living.
Measures: At baseline, cognitive functioning (assessed by the Mini-Mental Stand Examination), left and right hippocampal volume (assessed by magnetic resonance imaging), and APOE genotype were obtained.
Patients completed detailed measures at baseline, 15 weeks (end of treatment), 6 and 12 months post-randomisation with 12 months being the primary outcome point.
A total of 155 children (56% females; intervention n = 84, control n = 71) took part and completed measures at baseline (week 0) and post-intervention (week 11).
RESULTS All five clinical measures at baseline were significant predictors of the EQ index at 3 months and 12 months, except that MMSE was not significantly associated with the EQ index at 12 months.
There were no significant differences between the groups on the outcome measures at baseline (t (1, 124) = 0.02 1.38, p = .17 .98).17 .98
Outcome measures at baseline were also similar except for the mean GHQ scores, which were higher in the intervention group (Table 2).
Also, participants will complete the following measures at baseline: 1).
